The current CDC guidelines also recommend non-replicating adenovirus vector-based DNA vaccines for primary and booster vaccination in all populations. (a) True (b) False
The correct answer and explanation is:
Correct Answer: (b) False
Explanation:
The Centers for Disease Control and Prevention (CDC) does not currently recommend non-replicating adenovirus vector-based DNA vaccines for primary and booster vaccination in all populations. Specifically, the Johnson & Johnson (Janssen) COVID-19 vaccine, which utilizes a non-replicating adenovirus vector, was previously authorized for emergency use in the United States. However, due to safety concerns, including an increased risk of Guillain-Barré Syndrome and thrombosis with thrombocytopenia syndrome (TTS), the CDC and the Advisory Committee on Immunization Practices (ACIP) issued a clinical preference for mRNA vaccines (Pfizer-BioNTech and Moderna) over the Johnson & Johnson vaccine. As of May 2023, the Johnson & Johnson COVID-19 vaccine was discontinued in the U.S., and its Emergency Use Authorization (EUA) was revoked in June 2023 upon the manufacturer’s request due to reduced demand and the availability of other vaccines .(verywellhealth.com)
While non-replicating adenovirus vector-based vaccines, such as the AstraZeneca (AZD1222) and Sputnik V vaccines, have been used in other countries, their use is not universally recommended. The CDC’s current recommendations prioritize mRNA vaccines for COVID-19 vaccination due to their safety profiles and effectiveness.(pmc.ncbi.nlm.nih.gov)
Therefore, the statement that the CDC recommends non-replicating adenovirus vector-based DNA vaccines for primary and booster vaccination in all populations is false.